Lymphoma and cancer expert at MSKCC. Tweets and opinions are mine. RT and favorite = look
The final act! Grateful for the opportunity to work with those bright young scientists ... Optimistic about the future
.. and stopped at the office to sign >200 “delegation of authority “ for clinical trials...Happy to sign the very last one...Done!
#ASCO20 : Interesting data on Liso-Cel in 2nd line, transplant ineligible aggressive B cell lymphoma. 25 patients treated , 48% had primary refractory lymphoma. ORR 80%, CR 48%. Would be important to see CR rate in primary refractory patients
First-in-human data of ALLO-501 and ALLO-647 in relapsed/refractory large B-cell or follicular lymphoma (R/R LBCL/FL): ALPHA study. Only 9 pos treated, ORR 78% with manageable toxicity, with no GVHD. Too early to determine durability of responses
Phase I AUTO3, CD19/22 dual targeting CAR T cell therapy, in R/R DLBCL: of 11 treated at dose > 50 x 106, ORR and CRR were 64% and 55%. Looks safe, but durability of responses will be something to watch to determine the clinical benefit over CD19 CARs.
Results of a phase III randomized trial of zanubrutinib versus ibrutinib for patients with Waldenström macroglobulinemia (WM). Although did not meet the primary endpoint CR+VGPR was 28.4% vs 19.2% with ZANU vs IBR, respectively. Need to see KM-PFS curves
In Clinic: Nothing is more gratifying than helping patients achieve a remission and go back to their normal lives (PET scan image of an 81 year man with diffuse large B cell lymphoma before (left) and after 2 cycles of therapy)
Another long day at #ASH16 . Highlights of the day: three randomized studies in DLBCL were all unfortunately negative. RCHOP remains standard
Less is better in DLBCL: Two studies showed 4 is as good as 6 cycles of RCHOP in early stage non bulky good risk patients, and 6 is as good as 8 cycles of RCHOP in advanced stage DLBCL #ASH18